In short
Clinical trials are investigating ANHYDROUS MANGAFODIPIR TRISODIUM in people with heart failure, especially heart failure with preserved ejection fraction (HFpEF). The study data focus on how it performs in MRI research and whether manganese uptake can be measured in the heart.
Key points
- One clinical trial in the data studied ANHYDROUS MANGAFODIPIR TRISODIUM in people with heart failure, including heart failure with preserved ejection fraction (HFpEF). It was a Phase 2 interventional study with 42 participants. The main goal was to measure manganese uptake rate in the left ventricular wall during MRI research. The trial was completed. The study focused on whether this imaging approach could quantify how the heart takes up manganese after ANHYDROUS MANGAFODIPIR TRISODIUM was given.
Trial overview
Only one clinical trial was provided for ANHYDROUS MANGAFODIPIR TRISODIUM. It studied the substance in a heart failure setting and used MRI to measure manganese uptake in the heart.
The trial was completed and included 42 participants.
Who was studied
The target population was people with heart failure, especially those with heart failure with preserved ejection fraction (HFpEF).
HFpEF is a type of heart failure where the heart may still pump out blood, but it does not relax and fill normally.
Study design and phase
This was an interventional study, which means researchers gave a study intervention and then measured the effect.
The trial was in Phase 2, a stage that usually looks more closely at how well a study approach works in a specific group of patients.
The intervention list included ANHYDROUS MANGAFODIPIR TRISODIUM given by intravenous administration, along with Dotarem as another imaging-related drug in the study record.
What was measured
The primary endpoint was the determination of the manganese uptake rate.
An endpoint is the main result that researchers plan to measure in a trial.
The brief summary says the study aimed to quantify the manganese uptake rate after administration of mangafodipir trisodium in all segments of the left ventricular wall.
Trial details
The trial title describes ANHYDROUS MANGAFODIPIR TRISODIUM as an intracellular contrast agent for Magnetic Resonance Imaging (MRI) in patients with heart failure and preserved ejection fraction.
“Contrast agent” means a substance used in imaging tests to help body parts show up more clearly.
The study status was completed, so the trial record indicates that enrollment and follow-up were finished.
Patient-friendly terms
- Heart failure: the heart does not pump blood as well as it should.
- Preserved ejection fraction: the heart still pumps out a normal amount of blood, but it may not fill properly.
- Left ventricular wall: the muscle wall of the heart’s main pumping chamber.
- Intravenous administration: giving a substance through a vein.
- Manganese uptake rate: how much manganese is taken up by the heart tissue over time.